Stockscreener 앱 받기
8.25
4.43%
0.35
시간 외 거래:
8.25
전일 마감가:
$7.90
열려 있는:
$7.92
하루 거래량:
705.83K
Relative Volume:
0.70
시가총액:
$549.45M
수익:
$80.00M
순이익/손실:
$-74.88M
주가수익비율:
-6.9844
EPS:
-1.1812
순현금흐름:
$-60.38M
1주 성능:
+4.43%
1개월 성능:
+7.84%
6개월 성능:
-14.42%
1년 성능:
+171.38%
1일 변동 폭
$7.86
$8.25
1주일 범위
$7.40
$8.25
52주 변동 폭
$2.92
$15.74
Fulcrum Therapeutics Inc Stock (FULC) Company Profile
명칭
Fulcrum Therapeutics Inc
전화
617-651-8851
주소
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare FULC vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FULC
Fulcrum Therapeutics Inc
|
8.25 | 526.14M | 80.00M | -74.88M | -60.38M | -1.1812 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Fulcrum Therapeutics Inc Stock (FULC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-12 | 개시 | JP Morgan | Overweight |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-07-29 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-23 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-05-15 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-09-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-09-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-09-12 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2024-09-12 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-09-12 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-09-12 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-09-09 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-03-13 | 개시 | RBC Capital Mkts | Outperform |
| 2023-09-25 | 개시 | Goldman | Neutral |
| 2023-08-23 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-08-22 | 업그레이드 | Stifel | Hold → Buy |
| 2023-05-04 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-03-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-03-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-03-09 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-02-28 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-02-24 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-11-15 | 개시 | Goldman | Buy |
| 2022-03-08 | 개시 | Oppenheimer | Outperform |
| 2022-03-03 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-08-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2021-03-22 | 개시 | Credit Suisse | Outperform |
| 2021-03-02 | 개시 | Stifel | Buy |
| 2020-10-16 | 개시 | Piper Sandler | Overweight |
| 2020-08-12 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2020-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-12 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-06-19 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2019-10-03 | 개시 | H.C. Wainwright | Buy |
| 2019-08-12 | 개시 | BofA/Merrill | Buy |
모두보기
Fulcrum Therapeutics Inc 주식(FULC)의 최신 뉴스
Truist Securities Initiates Coverage of Fulcrum Therapeutics (FULC) with Buy Recommendation - MSN
Applied Digital, Simply Good Foods And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Sahm
Can Fulcrum Therapeutics Inc maintain sales growth2026 Macro Moves & AI Enhanced Trading Alerts - baoquankhu1.vn
Fundamentals Check: Is Fulcrum Therapeutics Inc stock influenced by commodity prices2026 Risk Factors & Reliable Price Breakout Signals - baoquankhu1.vn
Published on: 2026-04-08 00:16:15 - baoquankhu1.vn
Nasdaq Moves: Will Fulcrum Therapeutics Inc outperform tech stocksPortfolio Update Report & Risk Managed Trade Strategies - baoquankhu1.vn
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Earnings Miss: Can Fulcrum Therapeutics Inc deliver alphaProfit Target & High Return Trade Opportunity Guides - baoquankhu1.vn
Leerink reiterates Fulcrum Therapeutics stock rating on FDA flexibility By Investing.com - Investing.com Canada
Fulcrum Therapeutics (NASDAQ:FULC) Sees Strong Trading VolumeStill a Buy? - MarketBeat
Fulcrum Therapeutics Inc (FULC) Stock Price Quote Today & Current Price Chart | Capital.com Australia - Capital.com
Fulcrum Therapeutics Inc (FULC) Stock Price Quote Today & Current Price Chart - Capital.com
Aug Breakouts: Whats the fair value of Fulcrum Therapeutics Inc stockPortfolio Risk Report & Reliable Intraday Trade Alerts - baoquankhu1.vn
Avis Budget Group, Toyota Motor And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
Investor Mood: Will Fulcrum Therapeutics Inc outperform tech stocksTrade Exit Report & Community Trade Idea Sharing - baoquankhu1.vn
Vanguard entities disaggregate Fulcrum holdings (FULC) after internal realignment - Stock Titan
S P Trends: What hedge funds are buying Fulcrum Therapeutics Inc2026 Big Picture & Real-Time Stock Entry Alerts - baoquankhu1.vn
Institution Moves: Is Fulcrum Therapeutics Inc forming higher highs and higher lows2026 Earnings Surprises & Weekly Market Pulse Updates - baoquankhu1.vn
Fulcrum Therapeutics, Inc.(NasdaqGM:FULC) added to S&P Pharmaceuticals Select Industry Index - marketscreener.com
Growth Value: What hedge funds are buying Fulcrum Therapeutics IncMarket Sentiment Report & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Profit Recap: Can Fulcrum Therapeutics Inc deliver alpha2026 Retail & Weekly Return Optimization Alerts - baoquankhu1.vn
Fulcrum Extends Pociredir Program With Long-Term Sickle Cell Study - TipRanks
Is Fulcrum Therapeutics Inc benefiting from innovation trends2026 Closing Moves & Stepwise Swing Trade Plans - baoquankhu1.vn
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease - The Manila Times
MedicAlert Foundation, Sickle Cell Disease Association of - GlobeNewswire
Fulcrum Therapeutics Touts PIONEER HbF Gains, Early VOC Signal; FDA Path and Accelerated Approval Talk - Defense World
Short Interest in Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Rises By 19.7% - MarketBeat
Boothbay Fund Management Increases Stake in Fulcrum Therapeutics - National Today
Fulcrum Therapeutics, Inc. $FULC Shares Bought by Boothbay Fund Management LLC - MarketBeat
Wall Street analysts think Fulcrum Therapeutics (FULC) could surge 58.47%: Read this before placing a bet - MSN
219,488 Shares in Fulcrum Therapeutics, Inc. $FULC Bought by Braidwell LP - MarketBeat
Suvretta Capital Management LLC Raises Holdings in Fulcrum Therapeutics, Inc. $FULC - MarketBeat
Whats next for Fulcrum Therapeutics Inc stock2026 Winners & Losers & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Aug Macro: What’s next for Fulcrum Therapeutics Inc. stock2026 EndofYear Setup & Free Verified High Yield Trade Plans - baoquankhu1.vn
Fulcrum Therapeutics at Leerink Conference: Strategic Focus on Sickle Cell - Investing.com India
Fulcrum Therapeutics at Leerink Conference: Strategic Focus on Sickle Cell By Investing.com - Investing.com Canada
FULC: Pivotal study planned after robust PIONEER results, with focus on severe sickle cell and U.S. launch - TradingView
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Fulcrum Therapeutics (FULC) Stock Analysis Report | Financials & Insights - Benzinga Japan
Fulcrum Therapeutics stock may face pressure on Ipsen withdrawal, Stifel says - Investing.com Canada
Why Fulcrum Therapeutics Inc. stock appeals to dividend seekersJuly 2025 Highlights & Daily Price Action Insights - Naître et grandir
Bullish analyst sentiment on Fulcrum Therapeutics (FULC) following positive updates from Phase 1b PIONEER study - MSN
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Bull Run: Can Fulcrum Therapeutics Inc disrupt its industryJuly 2025 Price Swings & Reliable Trade Execution Plans - baoquankhu1.vn
Fulcrum Therapeutics to Participate in the Leerink Partners Global Healthcare Conference - 富途牛牛
Hedge Fund Moves: Is Fulcrum Therapeutics Inc part of any ETFJuly 2025 Reactions & Daily Profit Maximizing Tips - baoquankhu1.vn
FULC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Fulcrum Therapeutics (NASDAQ:FULC) Stock Price Down 7.5%Here's Why - MarketBeat
FULC Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Winners Losers: Can Fulcrum Therapeutics Inc keep up with sector leadersBond Market & Stepwise Swing Trade Plans - baoquankhu1.vn
Fulcrum Therapeutics Inc (FULC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):